Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GlycoMimetics, Inc. - Common Stock (NQ: GLYC )

0.2600 +0.0078 (+3.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GlycoMimetics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results
Via Benzinga
GlycoMimetics Shares Are Soaring Tuesday: Here's Why
GlycoMimetics, Inc. (NASDAQ:GLYC) shares are moving higher on Tuesday after the company announced it will merge with Crescent Biopharma. The company also said it secured $200 million in funding to... 
Via Benzinga
Why GlycoMimetics Stock is Trading Higher Monday
On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305 thousand shares in the company. 
Via Benzinga
Earnings Outlook For GlycoMimetics
Via Benzinga
Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
US Stocks Mixed; McDonald's Posts Upbeat Earnings
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
7 Sorry Biotech Stocks Set to Make Investors Sad
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning! 
Via InvestorPlace
$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024
GLYC stock results show that GlycoMimetics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
Via Benzinga
Topics Earnings
Exposures Financial
GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink
Get insights on GlycoMimetics Inc's Phase 3 study results for uproleselan in R/R AML patients. Explore survival rates, adverse events, and future analyses. 
Via Benzinga
Why Is Acutus Medical (AFIB) Stock Down 41% Today?
Acutus Medical stock is down on Monday after the company reported a delisting notice that will hit AFIB shares later this week. 
Via InvestorPlace
Why Is GlycoMimetics (GLYC) Stock Down 77% Today?
GlycoMimetics stock is falling on Monday with heavy trading of GLYC after posting lackluster results from a Phase 3 trial of uproleselan. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Monday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023
GLYC stock results show that GlycoMimetics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Earnings Scheduled For March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.